Asthma

Global Asthma Spacers Market 2019-2023: Increase in Online Retailing to Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 8, 2019
Health, General Health, Medical equipment, Respiratory therapy, Asthma spacer, Asthma, Compound annual growth rate, Medicine, Health, Applied mathematics

The "Global Asthma Spacers Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Asthma Spacers Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The asthma spacers market will register a CAGR of more than 4% by 2023.
  • The trend of online shopping has significantly increased with the ease of shopping that is from the comfort of one's home.
  • This drives growth in the asthma spacers market.

Global Asthma Spacers Market 2019-2023 | Increase in Online Retailing to Drive Growth | Technavio

Retrieved on: 
Tuesday, January 8, 2019
Health, General Health, Respiratory therapy, Medicine, Health, Medical equipment, Asthma spacer, Asthma, Respiratory therapist, Compound annual growth rate, Spacer

The global asthma spacers market research report by Technavio predicts the market to post a CAGR of more than 4% during the period 2019-2023.

Key Points: 
  • The global asthma spacers market research report by Technavio predicts the market to post a CAGR of more than 4% during the period 2019-2023.
  • View the full release here: https://www.businesswire.com/news/home/20190108005655/en/
    Technavio predicts the global asthma spacers market to post a CAGR of more than 4% by 2023.
  • (Graphic: Business Wire)
    A key driver for the global asthma spacers market is the growing demand for respiratory care.
  • During the forecast period, with the increasing use of asthma spacers, the rise in online retail of these products will facilitate the growth of the global asthma spacers market, says a senior analyst at Technavio for research on health care equipment & services.

RCSI Researchers Develop New Tuberculosis Treatment

Retrieved on: 
Tuesday, January 8, 2019
Tuberculosis, Medicine, Health, Dosage forms, Pharmacology, Asthma, Respiratory therapy, Inhaler, Metered-dose inhaler, Tuberculosis management

Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB).

Key Points: 
  • Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB).
  • This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
  • The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient's immune system fight the disease.
  • Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler.

Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market

Retrieved on: 
Wednesday, December 19, 2018
Medicine, Health, Chronic lower respiratory diseases, Herbalism, Medicinal plants, Respiratory therapy, Respiratory diseases, Chronic obstructive pulmonary disease, Cannabis, Chronic condition, Asthma, Medical cannabis

An upcoming independent analyst research report on Kali-Extracts from Goldman Small Cap Research is expected to include a more comprehensive analysis of Kali-Extracts overall body of cannabis biotechnologies.

Key Points: 
  • An upcoming independent analyst research report on Kali-Extracts from Goldman Small Cap Research is expected to include a more comprehensive analysis of Kali-Extracts overall body of cannabis biotechnologies.
  • The experiments were designed to evaluate pure cannabis extracts and cannabis extracts in combination with other therapies in the treatment of chronic obstructive pulmonary disease (COPD) and Asthma.
  • Based on the promising results of the respiratory treatment preclinical research study, NCM Biotech initiated a physiological study which has since been concluded with the research report to be forthcoming soon.
  • The treatment of COPD is currently estimated to be $5 billion in the United States and $11 billion worldwide.

Chronic Respiratory Disease Drug Development Pipeline Review, 2018: Therapeutics Development, Assessment, Companies, Dormant Projects, Discontinued Projects & Product Development Milestones

Retrieved on: 
Monday, December 17, 2018
Medicine, Pulmonology, Respiratory system, Respiratory therapy, Chronic lower respiratory diseases, RTT, Idiopathic pulmonary fibrosis, Asthma, Pulmonary function testing, Respiratory disease, Pulmonary fibrosis, Chronic cough

The "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Respiratory Disease Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for chronic respiratory diseases.
  • It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
  • Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing.

Lower-priced spacer chambers could compromise young asthma patients' treatment

Retrieved on: 
Wednesday, December 12, 2018
Respiratory therapy, Health, Medicine, Dosage forms, Medical equipment, Asthma, Asthma spacer, Inhaler, Spacer

LONDON, ON, Dec. 12, 2018 /CNW/ -When spacer chambers were introduced in the 1980s, they were a game changer in asthma treatment, overcoming the challenges faced by users with poor inhaler technique.

Key Points: 
  • LONDON, ON, Dec. 12, 2018 /CNW/ -When spacer chambers were introduced in the 1980s, they were a game changer in asthma treatment, overcoming the challenges faced by users with poor inhaler technique.
  • Both chambers have a mask and are suitable for children from 1 to 5 years old.
  • Using a spacer chamber is critical for young people to overcome obstacles to the drug making its way to the lungs.
  • Focusing only on a lower price could result in the selection of a spacer chamber that can compromise efficacy.

Nationwide asthma study from Propeller Health demonstrates clear link between air pollution and rescue inhaler use

Retrieved on: 
Tuesday, November 27, 2018
Health, Respiratory therapy, Health informatics, Medicine, Air pollution, Asthma, Inhaler, Digital medicine, Digital therapeutics

MADISON, Wis., Nov. 27, 2018 /PRNewswire/ --New research from Propeller Health, the University of Wisconsin-Madison and the University of California, Berkeley, is the first nationwide study to show an association between daily air pollution and rescue inhaler use using data obtained objectively from digital medicines.

Key Points: 
  • MADISON, Wis., Nov. 27, 2018 /PRNewswire/ --New research from Propeller Health, the University of Wisconsin-Madison and the University of California, Berkeley, is the first nationwide study to show an association between daily air pollution and rescue inhaler use using data obtained objectively from digital medicines.
  • The study, conducted from 2012 to 2017 on more than 2,800 people with asthma and published this week in Proceedings of the National Academy of Sciences, uses one of the largest nationwide datasets to assess the relationship between air pollution and asthma symptoms.
  • Unlike previous studies, which have largely relied on hospitalization or mortality data to assess the health impact of pollution, this study used nationwide data from Propeller's digital medicine database to analyze the level of fine particulate matter at the exact time and location of a person's rescue inhaler use.
  • Propeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines.

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

Retrieved on: 
Thursday, November 15, 2018
Chemistry, Health, Organic chemistry, Respiratory therapy, Chloroarenes, Dioxolanes, Itraconazole, Lactams, Piperazines, Asthma, Corticosteroid, Medication

Jim Roach, MD, FACP, FCCP, Chief Medical Officer at Pulmatrix Inc will present this data in a poster presentation entitled: "A Phase 1/1b Study of an Inhaled Formulation of Itraconazole in Healthy Volunteers and Asthmatics."

Key Points: 
  • Jim Roach, MD, FACP, FCCP, Chief Medical Officer at Pulmatrix Inc will present this data in a poster presentation entitled: "A Phase 1/1b Study of an Inhaled Formulation of Itraconazole in Healthy Volunteers and Asthmatics."
  • Oral itraconazole (Sporanox) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.
  • Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology.
  • The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations.

Patient Advocates, Medical Professionals and Industry Stakeholders Unite to Curb Oral Corticosteroid Overexposure in Asthma Treatment

Retrieved on: 
Thursday, November 15, 2018
Medicine, Health, Immunology, Respiratory therapy, Immune system, Allergy, RTT, Asthma, Asthma Canada

Allergy & Asthma Network is partnering with allergy and asthma patient advocacy groups, medical professional societies and industry stakeholders to raise awareness of OCS stewardship and develop strategies to curb reliance on OCS.

Key Points: 
  • Allergy & Asthma Network is partnering with allergy and asthma patient advocacy groups, medical professional societies and industry stakeholders to raise awareness of OCS stewardship and develop strategies to curb reliance on OCS.
  • Five to 10 percent of the total asthma population are believed to have severe asthma.
  • While the medication has been shown to reduce ED visits and hospitalizations, it may be used chronically in severe asthma patients.
  • Read the full Oral Corticosteroid Stewardship Statement, with the complete list of patient advocates, medical professionals and industry stakeholders, at https://bit.ly/2PwFR7z .

American College of Chest Physicians Disagrees with FDA Decision to Approve Over-the-Counter Epinephrine for the Treatment of Asthma

Retrieved on: 
Friday, November 9, 2018
Respiratory therapy, Health, Medicine, Pulmonology, Asthma, American College of Chest Physicians, Epinephrine

GLENVIEW, Ill., Nov. 9, 2018 /PRNewswire/ -- The American College of Chest Physicians (CHEST) is disappointed with the FDA's decision to approve over-the-counter epinephrine (Primatene Mist HFA) for the treatment of asthma.

Key Points: 
  • GLENVIEW, Ill., Nov. 9, 2018 /PRNewswire/ -- The American College of Chest Physicians (CHEST) is disappointed with the FDA's decision to approve over-the-counter epinephrine (Primatene Mist HFA) for the treatment of asthma.
  • Our membership of over 19,000 members from around the world provide patient care in pulmonary, critical care, and sleep medicine.
  • The majority of asthma patients require treatment with a controller medication, which is available only by prescription.
  • For information about the American College of Chest Physicians, and its flagship journalCHEST, visit chestnet.org.